10-Q: Blade Air Mobility Q2 Sees Profit Surge, Passenger Unit Sold

Blade Air Mobility reported a significant reduction in net loss and a swing to positive Adjusted EBITDA in Q2 2025, alongside the strategic sale of its Passenger business to Joby Aviation for up to $125 million.

Summary

• Net loss significantly improved by 67.0% to $3.7 million for the three months ended June 30, 2025, compared to $11.3 million in the prior year period.
• Adjusted EBITDA turned positive, increasing by 233.0% to $3.2 million for the three months ended June 30, 2025, up from $1.0 million in the same period of 2024.
• Total revenue increased by 4.2% to $70.8 million for the three months ended June 30, 2025, from $67.9 million in 2024.
• Medical Segment revenue grew by 17.6% to $45.1 million for the three months ended June 30, 2025, driven by new contracted customers.
• Passenger Segment revenue decreased by 13.2% to $25.7 million for the three months ended June 30, 2025, primarily due to the termination of Canada routes and lower US demand, partially offset by growth in Europe.
• The company entered into an agreement on August 1, 2025, to sell its Passenger business to Joby Aviation, Inc. for up to $125 million, consisting of $90 million upfront cash/shares and a $35 million earn-out.
• Cash and cash equivalents increased to $58.8 million as of June 30, 2025, from $18.4 million at December 31, 2024.
• Net cash used in operating activities significantly decreased to $3.3 million for the six months ended June 30, 2025, from $7.1 million in the prior year period.
• Total liquidity stood at $113.4 million as of June 30, 2025, comprising $58.8 million in cash and cash equivalents and $54.7 million in short-term investments.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance improvements, significantly reducing net losses and achieving positive Adjusted EBITDA. The strategic divestiture of the Passenger business to Joby Aviation provides a substantial cash infusion and allows for a focused approach on the high-growth Medical segment, enhancing long-term prospects despite some revenue declines in the divested segment.

Positives

• Net loss improved significantly by 67.0% for the three months ended June 30, 2025, and by 53.5% for the six months ended June 30, 2025.
• Adjusted EBITDA turned positive, reaching $3.2 million for Q2 2025 and $2.0 million for H1 2025, indicating improved operational efficiency.
• Medical Segment revenue showed strong growth of 17.6% in Q2 2025 and 9.0% in H1 2025, driven by new customer contracts.
• Passenger Segment Adjusted EBITDA improved substantially, swinging from a loss of $1.9 million in H1 2024 to a profit of $2.4 million in H1 2025, largely due to stronger performance in Europe and the discontinuation of less profitable Canada routes.
• Cost of revenue as a percentage of revenue decreased, indicating improved gross margins (75% in Q2 2025 vs 76% in Q2 2024, and 76% in H1 2025 vs 78% in H1 2024).
• General and administrative expenses decreased by 19.9% in Q2 2025 and 11.5% in H1 2025, primarily due to the absence of a prior year impairment charge.
• Selling and marketing expenses decreased by 31.8% in Q2 2025 and 32.2% in H1 2025, reflecting reduced media spend and stock-based compensation.
• Net cash used in operating activities decreased from $7.1 million in H1 2024 to $3.3 million in H1 2025, demonstrating improved cash management from core operations.
• Net cash provided by investing activities significantly increased to $49.1 million in H1 2025, primarily from maturities of held-to-maturity investments.
• The strategic sale of the Passenger business to Joby Aviation for up to $125 million provides a substantial cash infusion and allows the company to focus on its higher-growth Medical segment.
• The company maintains strong liquidity with $113.4 million in cash and short-term investments as of June 30, 2025, sufficient for operational needs for at least the next 12 months.

Negatives

• Short Distance revenue decreased by 17.8% in Q2 2025 and 13.8% in H1 2025, primarily due to the termination of Canada routes and lower demand in the US.
• Interest income decreased due to lower invested balances compared to the prior year period.
• Accumulated deficit increased to $(194.1) million as of June 30, 2025, from $(186.9) million at December 31, 2024, reflecting continued net losses.
• Elevated maintenance and pilot costs for the owned fleet utilized by the Medical segment partially offset revenue growth in that segment.

Risks

• Continued occurrence of net losses.
• Adverse publicity stemming from accidents involving small aircraft, helicopters, or charter flights, particularly those involving third-party operators.
• The inability to successfully complete the sale of the Passenger business on a timely basis or at all, and any inability to realize the anticipated benefits of such transaction.
• Potential negative impact on stock price if investors believe the consideration received from the Passenger divestiture is not equivalent to the value of divested assets.
• Disruption to remaining businesses and management distraction due to the Passenger divestiture.
• Fluctuation in the value of any Joby Aviation common stock received as consideration for the Passenger business.
• Reliance on contractual relationships with certain transplant centers, hospitals, and Organ Procurement Organizations in the Medical segment.
• Competition in the organ transportation market, including from providers offering proprietary organ preservation technology or additional services.
• The continuing availability of organ donors and viable donor organs.
• Insufficient reimbursement and funding for organ transport costs.
• Reliance on third-party operators to provide and operate aircraft, and the availability of these operators to match demand.
• The possibility that third-party aircraft operators may illegally, improperly, or otherwise inappropriately operate branded aircraft.
• Uncertainty regarding the development, approval, and commercial acceptance of Electric Vertical Aircraft (EVA) technology, and potential delays in certification or widespread use.
• Impact of inflation on operating costs, particularly for owned aircraft (pilot salaries, fuel, insurance, parts, maintenance), which may not always be fully passed through to customers.
• Ongoing legal proceedings, such as the Drulias class action lawsuit, which could result in material adverse effects on financial position or results of operations.

Future Outlook

The company anticipates leveraging the expected lower operating costs of Electric Vertical Aircraft (EVA) to reduce flight prices and enable new vertiport development. The strategic sale of the Passenger business to Joby Aviation is expected to qualify as a discontinued operation, allowing the company to focus on its Medical segment. Future liquidity requirements will depend on expansion pace, customer retention, capital expenditures, and acquisitions.

Management Comments

• Management's opinion is that all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations and cash flows at the dates and for the periods presented have been included.
• We anticipate that we have sufficient funds to meet our current operational needs for at least the next 12 months from the date of filing this Quarterly Report.
• We believe that Blade is well positioned to introduce EVA into commercial service, once available, for a number of reasons.
• Our asset-light business model was developed to be scalable and profitable using conventional aircraft today while enabling a seamless transition to EVA, once they are certified for public use.

Industry Context

The company operates in two distinct but related segments: Passenger air mobility (helicopters, fixed-wing, transitioning to eVTOL) and Medical logistics (organ transport). The Passenger segment faces competition from various transportation modes and is undergoing a strategic divestiture to Joby Aviation, a key player in the eVTOL development space. The Medical segment operates in a highly competitive and time-sensitive market, focusing on reliability and efficiency for organ transportation. The broader industry is moving towards Electric Vertical Aircraft (EVA/eVTOL) technology, which promises lower operating costs, reduced noise, and zero emissions, potentially enabling new infrastructure development.

Comparison to Industry Standards

• The organ transportation market is highly competitive, with the company competing against providers offering proprietary organ preservation technology or additional services like surgical organ recovery.
• The private jet charter market has seen significant increases in demand in recent years, leading to increased charter costs and limited availability, which could impact the company's Jet and Other product line.
• The development of Electric Vertical Aircraft (EVA) technology is a complex industry-wide effort, with no EVA aircraft currently certified by the FAA for commercial operations in the United States, indicating the nascent stage of this technology across the sector.

Legal Proceedings

• Two putative class action lawsuits, consolidated under Drulias et al. v. Affeldt, et al., C.A. No. 2024-0161-SG (Del. Ch.), were filed in February 2024 relating to the acquisition of Blade Urban Air Mobility, Inc. (Old Blade).
• Plaintiffs assert claims for breach of fiduciary duty and unjust enrichment against former directors and officers of Experience Investment Corp. (EIC) and Experience Sponsor LLC (Sponsor), and aiding and abetting breach of fiduciary duty against Sponsor.
• The operative complaint alleges insufficient disclosure in the proxy statement related to the Old Blade acquisition, concerning EIC's cash position, Old Blade's value prospects and risks, and information related to Old Blade's chief executive officer.
• The consolidated complaint seeks damages and attorneys' fees and costs.
• The company believes all claims are without merit and intends to defend itself vigorously.

Stakeholder Impact

• Shareholders: Potential positive impact from improved financial performance, significant cash infusion from the Passenger business sale, and a clearer strategic focus on the Medical segment. However, risks include the potential for the sale not to close, fluctuations in the value of Joby Aviation shares received, and the divested segment's value perception.
• Employees: Employee retention targets are part of the earn-out structure in the Passenger business sale, indicating a focus on retaining key personnel during the transition.
• Customers: Medical segment customers can expect continued and potentially enhanced service due to the company's increased focus and investment in this area. Passenger customers will transition to Joby Aviation's operations.
• Creditors: Improved liquidity and a stronger balance sheet post-divestiture could enhance the company's creditworthiness.

Next Steps

• Consummation of the Equity Purchase Agreement for the sale of the Passenger business to Joby Aviation, Inc.
• Satisfaction or waiver of certain closing conditions related to the Passenger business sale.
• Potential receipt of up to $35.0 million earn-out from Joby Aviation based on employee retention and financial performance targets over 12 and 18 months following the closing.
• Evaluation of the impact of the 'One Big Beautiful Bill Act' on U.S. federal income tax laws on financial statements and results of operations.
• Continued evaluation of new accounting pronouncements (ASU 2023-06, 2023-09, 2024-03) for their impact on financial statements and disclosures.
• Leveraging the asset-light business model and technology platform to enable a seamless transition to Electric Vertical Aircraft (EVA) once certified for public use.

Key Dates

Recommendation

The company has demonstrated a significant turnaround in its financial performance, moving towards profitability with a substantial reduction in net loss and a positive swing in Adjusted EBITDA. The strategic divestiture of the Passenger business, while reducing overall revenue, provides a significant cash infusion of up to $125 million and allows the company to concentrate resources on its high-growth, high-margin Medical segment. This focus on a more resilient and profitable core business, coupled with improved liquidity and cash flow from operations, positions the company for stronger future performance. The risks associated with the divestiture and the nascent eVTOL market are present but appear manageable given the strategic clarity and financial strengthening.

Keywords

Blade Air Mobility, BLDE, Joby Aviation, eVTOL, Urban Air Mobility, Organ Transport, MediMobility, Aviation, Air Charter, SEC Filing, 10-Q, Quarterly Report